Cytel excels at using proven quantitative techniques to transform real-world data into actionable insights
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
PEEK brings a new quality to dental care for patients
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Dr. Vivek joins Healthium after a stint at Ethicon, Johnson & Johnson
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Subscribe To Our Newsletter & Stay Updated
